Search company, investor...


Founded Year



Series B | Alive

Total Raised


Last Raised

$5.71M | 10 mos ago

About PuREC

PuREC conducts R&D for therapeutic REC (Rapidly Expanding Cells) preparations and markets REC as research reagents. The company aims to establish practical applications of regenerative medicine technologies using bone marrow-derived mesenchymal stem cells (BM-MSCs).

Headquarters Location

Shimane Shimane University School of Medicine 89-1 Enya-cho

Izumo, 693-0021,


+81 0853-25-3033

Missing: PuREC's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: PuREC's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing PuREC

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PuREC is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

PuREC Patents

PuREC has filed 3 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Developmental biology
  • Stem cells
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Monoclonal antibodies, Stem cells, Biotechnology, Developmental biology


Application Date


Grant Date



Related Topics

Transcription factors, Monoclonal antibodies, Stem cells, Biotechnology, Developmental biology



Latest PuREC News

PURECYCLE 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against PureC...

Jul 11, 2021

. A NEW ORLEANS, La., July 11, 2021 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until July 12, 2021 to file lead plaintiff applications in securities class action lawsuits against PureCycle Technologies, Inc. (NasdaqCM: PCT) f/k/a Roth CH Acquisition I Co. ("Roth") (Nasdaq: ROCH), if they purchased PureCycle and/or Roth securities between November 16, 2020 and May 5, 2021, inclusive (the "Class Period") and/or were holders of Roth securities entitled to participate in the March 16, 2021 shareholder vote on the merger with PureCycle. These actions are pending in the United States District Court for the Middle District of Florida. What You May Do If you purchased and/or held securities of PureCycle and/or Roth as above and would like to discuss your legal rights and how these cases might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( ), or visit  to learn more. If you wish to serve as a lead plaintiff in the class actions, you must petition the Courts by July 12, 2021. About the Lawsuits PureCycle and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. Specifically, the action alleges that the Company failed to disclose that increases in commodity and freight costs had been negatively impacting the Company's business and operations. On May 6, 2021, pre-market, Hindenburg Research reported a wide range of criticisms toward the Company related to its prior "going public" transaction with Roth and present position, concluding that the Company "represents the worst qualities of the SPAC boom; another quintessential example of how executives and SPAC sponsors enrich themselves while hoisting unproven technology and ridiculous financial projections onto the public markets, leaving retail investors to face the ultimate consequences." On this news, shares of PureCycle plummeted more than 40%, or approximately $10 per share, on very unusually high trading volume. The first-filed case is Theodore v. PureCycle Technologies, Inc., et al., No. 21-cv-809. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana. To learn more about KSF, you may visit . Contact:

PuREC Frequently Asked Questions (FAQ)

  • When was PuREC founded?

    PuREC was founded in 2016.

  • Where is PuREC's headquarters?

    PuREC's headquarters is located at Shimane Shimane University School of Medicine, Izumo.

  • What is PuREC's latest funding round?

    PuREC's latest funding round is Series B.

  • How much did PuREC raise?

    PuREC raised a total of $11.78M.

  • Who are the investors of PuREC?

    Investors of PuREC include Gogin Capital, Mochida Pharmaceutical, Hiromitsu Nakauchi, San-in Godo Bank, Shimane University and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.